How does KUR's PB Ratio compare to its peers?

KUR is expensive based on its Price-To-Book Ratio (2x) compared to the peer average (1.9x).

How does KUR's PB Ratio compare vs other companies in the DE Biotechs Industry?

KUR is good value based on its Price-To-Book Ratio (2x) compared to the European Biotechs industry average (2.4x).

What is KUR's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate KUR's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of KUR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate KUR's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Kura Oncology (DB:KUR) - Stock Price, News & Analysis

KUR Stock Overview

A clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. More details

KUR fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 58.34% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Volatile share price over the past 3 months compared to the German market

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Kura Oncology, Inc. Competitors

Formycon

XTRA:FYB

€827.2m

Biotest

XTRA:BIO3

€1.4b

Heidelberg Pharma

XTRA:HPHA

€103.9m

2invest

XTRA:2INV

€63.8m

Price History & Performance

Summary of all time highs, changes and price drops for Kura Oncology
Historical stock prices
Current Share Price	US$9.96
52 Week High	US$21.40
52 Week Low	US$8.40
Beta	0.86
11 Month Change	-38.58%
3 Month Change	-44.19%
1 Year Change	16.51%
33 Year Change	-18.34%
5 Year Change	-29.35%
Change since IPO	39.56%

Recent updates

Shareholder Returns

	KUR	DE Biotechs	DE Market
7D	-34.9%	-0.7%	-0.02%
1Y	16.5%	-17.2%	8.2%

Return vs Industry: KUR exceeded the German Biotechs industry which returned -17.2% over the past year.

Return vs Market: KUR exceeded the German Market which returned 8.2% over the past year.

Price Volatility

Is KUR's price volatile compared to industry and market?
KUR volatility
KUR Average Weekly Movement	9.0%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.3%

Stable Share Price: KUR's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: KUR's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2014	142	Troy Wilson	kuraoncology.com

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

Kura Oncology, Inc. Fundamentals Summary

How do Kura Oncology's earnings and revenue compare to its market cap?
KUR fundamental statistics
Market cap	€806.51m
Earnings (TTM)	-€189.71m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-4.3x

P/E Ratio

Is KUR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KUR income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$197.55m
Earnings	-US$197.55m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-2.54
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	2.2%

How did KUR perform over the long term?

See historical performance and comparison

KUR Stock Overview

Rewards

Risk Analysis

Kura Oncology, Inc. Competitors

XTRA:FYB

€827.2m

XTRA:BIO3

€1.4b

XTRA:HPHA

€103.9m

XTRA:2INV

€63.8m

Price History & Performance

Recent News & Updates

Kura Oncology, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Kura Oncology, Inc. Appoints Michael Vasconcelles to Its Board of Directors

Kura Oncology Announces Fda Clearance of Ind Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (Gist)

Kura Oncology, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Now 20% undervalued

Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell 2500 Value Index

Recent updates

Kura Oncology, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Kura Oncology, Inc. Appoints Michael Vasconcelles to Its Board of Directors

Kura Oncology Announces Fda Clearance of Ind Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (Gist)

Kura Oncology, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Now 20% undervalued

Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell 2500 Value Index

Insufficient new directors

New minor risk - Share price stability

Kura Oncology, Inc. Completes Enrollment of 85 Patients in the Phase 2 Portion of KOMET-001

Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML

Kura Oncology, Inc. to Report Q1, 2024 Results on May 02, 2024

Kura Oncology, Inc. Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

Now 21% undervalued

Kura Oncology, Inc., Annual General Meeting, Jun 05, 2024

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

Kura Oncology, Inc. Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia

Kura Oncology, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Kura Oncology, Inc. Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

New major risk - Share price stability

Kura Oncology, Inc. announced that it expects to receive $150 million in funding from EcoR1 Capital, LLC

Kura Oncology, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Kura Oncology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Kura Oncology, Inc. Announces First Patient Dosed in Fit-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806

Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASG12C Inhibitors in Non-Small Cell Lung Cancer

Kura Oncology Appoints Brian Powl as Chief Commercial Officer

Kura Oncology, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Kura Oncology, Inc. has completed a Follow-on Equity Offering in the amount of $99.999707 million.

Kura Oncology, Inc. Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib At 2023 European Hematology Association Congress

Kura Oncology, Inc. to Report Q1, 2023 Results on May 10, 2023

Kura Oncology, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Kura Oncology, Inc. Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia

Chief Medical Officer recently sold €56k worth of stock

Kura Oncology Announces FDA Clearance of IND Application for KO-2806, A Next-Generation Farnesyl Transferase Inhibitor

Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib

Kura Oncology, Inc. announced that it expects to receive $150.000003 million in funding from Bristol-Myers Squibb Company,

Kura Oncology, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Kura Oncology, Inc. Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma

Kura Oncology, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Kura Oncology, Inc. Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer

Kura Oncology, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Kura Oncology, Inc. Announces Executive Changes

Kura Oncology, Inc. Announces Executive Changes

Kura Oncology, Inc. Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia

Kura Oncology, Inc. Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

Kura Oncology, Inc. Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma

Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia

Independent Director Robert Hoffman has left the company

Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell 3000E Index

Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539

New 90-day low: €22.00

Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma

Kura Oncology, Inc. to Report Q4, 2020 Results on Feb 24, 2021

New 90-day low: €24.40

Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 At American Society of Hematology Annual Meeting

New 90-day high: €29.40

Kura Oncology, Inc. to Report Q3, 2020 Results on Nov 05, 2020

Kura Oncology, Inc. Reports Preclinical Results Showing Antitumor Activity of Tipifarnib in Combination with PI3Ka Inhibitor in Head and Neck Squamous Cell Carcinoma

New 90-day high: €26.40

Kura Oncology, Inc. to Report Q1, 2020 Results on May 04, 2020